The premature ejaculation treatment market share will post an incremental growth of USD 1.26 billion, progressing at a CAGR of 9.06% during the forecast period. The high efficacy of off-label drugs will offer immense growth opportunities to market vendors. The premature ejaculation treatment market is fragmented, and the vendors are deploying growth strategies such as low-pricing strategies and strengthening the local customer base to compete in the market.
Technavio’s report on “Premature Ejaculation Treatment Market by Route of Administration, Drug Class, and Geography - Forecast and Analysis 2022-2026” provides a detailed analysis of the prevalent market forces, trends, and challenges likely to impact the market in focus.
The premature ejaculation treatment market is segmented by route of administration (oral and topical), drug class (SSRIs, PDE5 inhibitors, amide anesthetics, and others), and geography (North America, Europe, Asia, and the Rest of World (ROW)).
The growth of the premature ejaculation treatment market size in the oral segment will be significant during the forecast period. Factors such as the significant rise in the number of premature ejaculation cases, owing to psychological strain and stress from an ever-changing lifestyle will facilitate the premature ejaculation treatment market growth in North America. 39% of the market’s growth will originate from North America during the forecast period. The US is the key market for premature ejaculation treatment market in North America.
The high efficacy of off-label drugs will directly influence premature ejaculation treatment market growth. In addition, the advent of nanotechnology is one of the major premature ejaculation treatment market trends that will positively impact market growth. However, factors such as the availability of alternative treatment options will hamper the premature ejaculation treatment market growth.
The market is fragmented due to the presence of several players. Some of the major premature ejaculation treatment market vendors are A. Menarini Industrie Farmaceutiche Riunite Srl, Absorption Pharmaceuticals LLC, Alembic Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Aytu BioPharma Inc., Bayer AG, Cipla Ltd., Eli Lilly and Co., Endurance RP Ltd., GlaxoSmithKline Plc, Johnson and Johnson, Lupin Ltd., NeuroHealing Pharmaceuticals Inc., Novitium Pharma, Pfizer Inc., Plethora Solutions Ltd., Sandoz International GmbH, Solco Healthcare, and Teva Pharmaceutical Industries Ltd.
To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their position in the slow-growing segments. To survive and succeed in such an intensely competitive market, players must distinguish their product and service offerings through clear and unique value propositions.
Download the Free PDF sample report for highlights on the market size, growth momentum, regional growth opportunities, vendor analysis, and other factors influencing the market growth.
Precise market size estimation during the forecast period 2022-2026.
CAGR of the premature ejaculation treatment market forecast during 2022-2026.
Market-level data on units, average selling prices, and values of the premature ejaculation treatment market share.
Prediction of the upcoming trends, drivers, and factors that challenge the growth of the premature ejaculation treatment market.
Premature ejaculation treatment industry growth across North America, Europe, Asia, and the Rest of World (ROW).
